Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

[The cutting edge of epithelium-targeted drug development].

Kondoh M, Kunisawa J.

Yakugaku Zasshi. 2014;134(5):613. Japanese. No abstract available.

2.

[The new era of epithelium-targeted drug development].

Shimizu Y, Nagase S, Yagi K, Kondoh M.

Yakugaku Zasshi. 2014;134(5):641-5. Review. Japanese.

3.

Cutting-edge technologies in colon-targeted drug delivery systems.

Patel MM.

Expert Opin Drug Deliv. 2011 Oct;8(10):1247-58. doi: 10.1517/17425247.2011.597739.

PMID:
21933030
4.

Prodrug based optimal drug delivery via membrane transporter/receptor.

Yang C, Tirucherai GS, Mitra AK.

Expert Opin Biol Ther. 2001 Mar;1(2):159-75. Review.

PMID:
11727527
5.

Approaches towards enhanced transepithelial drug delivery.

Majumdar S, Mitra AK.

Discov Med. 2006 Dec;6(36):229-33.

6.

Nanotechnology and site-targeted drug delivery.

Petrak K.

J Biomater Sci Polym Ed. 2006;17(11):1209-19. Review.

PMID:
17176746
7.

Tumour endoproteases: the cutting edge of cancer drug delivery?

Atkinson JM, Siller CS, Gill JH.

Br J Pharmacol. 2008 Apr;153(7):1344-52. doi: 10.1038/sj.bjp.0707657. Review.

8.

Discovery of tight junction modulators: significance for drug development and delivery.

Johnson PH, Frank D, Costantino HR.

Drug Discov Today. 2008 Mar;13(5-6):261-7. doi: 10.1016/j.drudis.2007.10.023. Review.

PMID:
18342803
9.

[Recent advances in the study of dendrimers-based drug delivery systems].

Zheng C, Qiao MX, Yan L, Hu HY, Chen DW.

Yao Xue Xue Bao. 2007 Sep;42(9):924-9. Review. Chinese.

PMID:
18050732
10.

[New approach in drug designing: molecular-targeted drugs].

Tsuruo T.

Nihon Naika Gakkai Zasshi. 2002 Dec 10;91(12):3401-7. Japanese. No abstract available.

PMID:
12655675
11.

Membranes and Barriers: Targeted Drug Delivery. Proceedings from a technical review meeting. September 28-29, 1993.

[No authors listed]

NIDA Res Monogr. 1995;154:1-244. No abstract available.

PMID:
8606738
12.

[Exploiting functional dependencies in cancer cells for the development of targeted therapies].

Stolze B, Scholl C.

Dtsch Med Wochenschr. 2013 Jun;138(25-26):1369-72. doi: 10.1055/s-0033-1343244. Review. German. No abstract available.

PMID:
23761060
13.

Strategies on the development of small molecule anticancer drugs for targeted therapy.

Lu YH, Gao XQ, Wu M, Zhang-Negrerie D, Gao Q.

Mini Rev Med Chem. 2011 Jun;11(7):611-24. Review.

PMID:
21699492
14.

Delivery of bioactive peptides and proteins across oral (buccal) mucosa.

Senel S, Kremer M, Nagy K, Squier C.

Curr Pharm Biotechnol. 2001 Jun;2(2):175-86. Review.

PMID:
11480421
15.
16.

Targeted blood-to-brain drug delivery --10 key development criteria.

Gaillard PJ, Visser CC, Appeldoorn CC, Rip J.

Curr Pharm Biotechnol. 2012 Sep;13(12):2328-39. Review.

PMID:
23016639
17.

Design of thermally responsive, recombinant polypeptide carriers for targeted drug delivery.

Chilkoti A, Dreher MR, Meyer DE.

Adv Drug Deliv Rev. 2002 Oct 18;54(8):1093-111. Review.

PMID:
12384309
18.

Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging.

Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, GrazĂș V, Borm P, Estrada G, Ntziachristos V, Razansky D.

Part Fibre Toxicol. 2010 Mar 3;7:3. doi: 10.1186/1743-8977-7-3. Review.

19.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
20.

Controlled local delivery of tetracycline in the treatment of periodontitis.

Killoy WJ, Cobb CM.

Compendium. 1992 Dec;13(12):1150, 1152, 1154 passim. Review. No abstract available.

PMID:
1298560
Items per page

Supplemental Content

Support Center